Palatin Technologies is a biopharmaceutical company developing targeted receptor specific peptide therapeutics to treat diseases.
Palatin Technologies is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for treating diseases with significant unmet medical needs and commercial potential. Their programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Their primary product in clinical development is bremelanotide for treating female sexual dysfunction (FSD). In addition, they have drug candidates or development programs for obesity, erectile dysfunction, pulmonary diseases, cardiovascular diseases, and inflammatory diseases.Their current focus is on the design and development of receptor-selective melanocortin agonists for inflammation and autoimmune conditions, with a focus on ocular diseases. Their therapeutics work by activating endogenous melanocortin pathways to resolve damaging inflammation and allow affected tissues time to heal. Research has shown melanocortin agonists can prevent and reverse inflammation in disease models, including in the eyes and intestine—two of their targeted areas.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Dec 24, 2014 | Post-IPO Debt | $10M | 1 | — | — | Detail |
Jan 30, 2004 | Post-IPO Equity | $22.70M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Horizon Technology Finance | — | Post-IPO Debt |
Alexandra Investment Management | — | Post-IPO Equity |